التفاصيل البيبلوغرافية
| العنوان: |
Outcomes of relapse in patients with deferred autologous stem cell transplant after achieving at least very good partial response following bortezomib, adriamycin, dexamethasone chemotherapy for newly diagnosed multiple myeloma in the phase II PADIMAC trial |
| المؤلفون: |
Chan, Wei Yee, Counsell, Nicholas, de Tute, Ruth, De‐Silva, Dunnya, Phillips, Elizabeth H., Cavenagh, Jamie, Adedayo, Toyin, Braganca, Nivette, Roddie, Claire, Streetly, Matthew, Schey, Stephen, Koh, Mickey B.C., Crowe, Josephine, Morris, Treen C., Cook, Gordon, Clifton‐Hadley, Laura, Rabin, Neil, Owen, Roger G., Popat, Rakesh, Yong, Kwee L. |
| المصدر: |
British Journal of Haematology; Feb2022, Vol. 196 Issue 4, pe33-e37, 5p |
| مصطلحات موضوعية: |
STEM cell transplantation, MULTIPLE myeloma, DISEASE relapse, DOXORUBICIN, BORTEZOMIB |
| مستخلص: |
PADIMAC trial Multiple myeloma, autologous stem cell transplantation, high dose therapy, myeloma therapy Keywords: multiple myeloma; autologous stem cell transplantation; high dose therapy; myeloma therapy EN multiple myeloma autologous stem cell transplantation high dose therapy myeloma therapy e33 e37 5 02/14/22 20220215 NES 220215 Current Phase III trials demonstrate the benefit of up-front autologous stem cell transplant (ASCT) as standard of care for transplant-eligible newly diagnosed patients with multiple myeloma.1-3 Deeper responses and achievement of minimal residual disease (MRD) negativity with current triplet and quadruplet treatments4 has questioned timing and role of ASCT with deferral being preferable for some.5,6 Long-term analysis of the EMN02 trial shows that high-risk patients gain most survival benefit from up-front ASCT3 and such risk-stratified approach to ASCT with standard risk patients receiving deferred ASCT, may be acceptable.7 We previously reported primary results of the Phase II PADIMAC trial, which demonstrated a median progression-free survival (PFS) of 17-0 months [95% confidence interval (CI): 10-5-23-2] for 63 patients who achieved a very good partial response (VGPR) or better post induction and stopped treatment until disease progression.8 MRD-positive patients at day 100 had a median PFS of 9-9 months (95% CI: 5-8-23-2) compared to 24-8 months (95% CI: 18-3-34-2) for MRD-negative patients. [Extracted from the article] |
|
Copyright of British Journal of Haematology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
